Immunome (IMNM) just unveiled an update.
Immunome has acquired exclusive rights from Bristol-Myers Squibb to develop and commercialize the cancer-fighting compounds AL101 and AL102, marking a significant advancement in their potential to treat diseases. As part of the asset purchase agreement, Immunome paid Ayala $20 million in cash, issued over 2 million shares, and may pay additional milestone payments totaling up to $37.5 million. This strategic move positions Immunome to potentially revolutionize treatment options and underscores the high stakes in pharmaceutical innovation and the pursuit of groundbreaking therapies.
Learn more about IMNM stock on TipRanks’ Stock Analysis page.
